<code id='B9ED0F3730'></code><style id='B9ED0F3730'></style>
    • <acronym id='B9ED0F3730'></acronym>
      <center id='B9ED0F3730'><center id='B9ED0F3730'><tfoot id='B9ED0F3730'></tfoot></center><abbr id='B9ED0F3730'><dir id='B9ED0F3730'><tfoot id='B9ED0F3730'></tfoot><noframes id='B9ED0F3730'>

    • <optgroup id='B9ED0F3730'><strike id='B9ED0F3730'><sup id='B9ED0F3730'></sup></strike><code id='B9ED0F3730'></code></optgroup>
        1. <b id='B9ED0F3730'><label id='B9ED0F3730'><select id='B9ED0F3730'><dt id='B9ED0F3730'><span id='B9ED0F3730'></span></dt></select></label></b><u id='B9ED0F3730'></u>
          <i id='B9ED0F3730'><strike id='B9ED0F3730'><tt id='B9ED0F3730'><pre id='B9ED0F3730'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:937
          Brain cancer
          Michelle Monje/Stanford University/NIH

          Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

          The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

          advertisement

          “We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Readout LOUD: Venture capital, Gilead, and more M&A
          Readout LOUD: Venture capital, Gilead, and more M&A

          AreventurecapitalistsOK?Arebolt-onsgoodforbusiness?Andwhenisitsafetosaysomeoneoverpaid?Wecoveralltha

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Congress needs to close a vaccine

          VictorMoriyama/GettyImagesThePatientProtectionandAffordableCareAct,(generallyknownastheACA),wassigne